These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

681 related articles for article (PubMed ID: 29909005)

  • 1. Accuracy of Sensititre YeastOne echinocandins epidemiological cut-off values for identification of FKS mutant Candida albicans and Candida glabrata: a ten year national survey of the Fungal Infection Network of Switzerland (FUNGINOS).
    Kritikos A; Neofytos D; Khanna N; Schreiber PW; Boggian K; Bille J; Schrenzel J; Mühlethaler K; Zbinden R; Bruderer T; Goldenberger D; Pfyffer G; Conen A; Van Delden C; Zimmerli S; Sanglard D; Bachmann D; Marchetti O; Lamoth F;
    Clin Microbiol Infect; 2018 Nov; 24(11):1214.e1-1214.e4. PubMed ID: 29909005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Two Commercial Broth Microdilution Methods Using Different Interpretive Criteria for the Detection of Molecular Mechanisms of Acquired Azole and Echinocandin Resistance in Four Common
    Lim HJ; Shin JH; Kim MN; Yong D; Byun SA; Choi MJ; Lee SY; Won EJ; Kee SJ; Kim SH; Shin MG
    Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32900684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rate of FKS Mutations among Consecutive Candida Isolates Causing Bloodstream Infection.
    Shields RK; Nguyen MH; Press EG; Cumbie R; Driscoll E; Pasculle AW; Clancy CJ
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7465-70. PubMed ID: 26392494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.
    Alexander BD; Johnson MD; Pfeiffer CD; Jiménez-Ortigosa C; Catania J; Booker R; Castanheira M; Messer SA; Perlin DS; Pfaller MA
    Clin Infect Dis; 2013 Jun; 56(12):1724-32. PubMed ID: 23487382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring Antifungal Resistance in a Global Collection of Invasive Yeasts and Molds: Application of CLSI Epidemiological Cutoff Values and Whole-Genome Sequencing Analysis for Detection of Azole Resistance in Candida albicans.
    Castanheira M; Deshpande LM; Davis AP; Rhomberg PR; Pfaller MA
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the Sensititre YeastOne colorimetric antifungal panel with CLSI microdilution for antifungal susceptibility testing of the echinocandins against Candida spp., using new clinical breakpoints and epidemiological cutoff values.
    Pfaller MA; Chaturvedi V; Diekema DJ; Ghannoum MA; Holliday NM; Killian SB; Knapp CC; Messer SA; Miskou A; Ramani R
    Diagn Microbiol Infect Dis; 2012 Aug; 73(4):365-8. PubMed ID: 22726528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spontaneous Mutational Frequency and
    Shields RK; Kline EG; Healey KR; Kordalewska M; Perlin DS; Nguyen MH; Clancy CJ
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter study of epidemiological cutoff values and detection of resistance in Candida spp. to anidulafungin, caspofungin, and micafungin using the Sensititre YeastOne colorimetric method.
    Espinel-Ingroff A; Alvarez-Fernandez M; Cantón E; Carver PL; Chen SC; Eschenauer G; Getsinger DL; Gonzalez GM; Govender NP; Grancini A; Hanson KE; Kidd SE; Klinker K; Kubin CJ; Kus JV; Lockhart SR; Meletiadis J; Morris AJ; Pelaez T; Quindós G; Rodriguez-Iglesias M; Sánchez-Reus F; Shoham S; Wengenack NL; Borrell Solé N; Echeverria J; Esperalba J; Gómez-G de la Pedrosa E; García García I; Linares MJ; Marco F; Merino P; Pemán J; Pérez Del Molino L; Roselló Mayans E; Rubio Calvo C; Ruiz Pérez de Pipaon M; Yagüe G; Garcia-Effron G; Guinea J; Perlin DS; Sanguinetti M; Shields R; Turnidge J
    Antimicrob Agents Chemother; 2015 Nov; 59(11):6725-32. PubMed ID: 26282428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure.
    Shields RK; Nguyen MH; Press EG; Updike CL; Clancy CJ
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3528-35. PubMed ID: 23669387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.
    Pfaller MA; Diekema DJ; Andes D; Arendrup MC; Brown SD; Lockhart SR; Motyl M; Perlin DS;
    Drug Resist Updat; 2011 Jun; 14(3):164-76. PubMed ID: 21353623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations.
    Lepak A; Castanheira M; Diekema D; Pfaller M; Andes D
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5875-82. PubMed ID: 22948870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains.
    Castanheira M; Woosley LN; Diekema DJ; Messer SA; Jones RN; Pfaller MA
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2655-9. PubMed ID: 20368396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata.
    Shields RK; Nguyen MH; Press EG; Kwa AL; Cheng S; Du C; Clancy CJ
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4862-9. PubMed ID: 22751546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical perspectives on echinocandin resistance among Candida species.
    Shields RK; Nguyen MH; Clancy CJ
    Curr Opin Infect Dis; 2015 Dec; 28(6):514-22. PubMed ID: 26524326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance.
    Pfaller MA; Messer SA; Woosley LN; Jones RN; Castanheira M
    J Clin Microbiol; 2013 Aug; 51(8):2571-81. PubMed ID: 23720791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia.
    Beyda ND; John J; Kilic A; Alam MJ; Lasco TM; Garey KW
    Clin Infect Dis; 2014 Sep; 59(6):819-25. PubMed ID: 24879785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance.
    Zimbeck AJ; Iqbal N; Ahlquist AM; Farley MM; Harrison LH; Chiller T; Lockhart SR
    Antimicrob Agents Chemother; 2010 Dec; 54(12):5042-7. PubMed ID: 20837754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anidulafungin and micafungin MIC breakpoints are superior to that of caspofungin for identifying FKS mutant Candida glabrata strains and Echinocandin resistance.
    Shields RK; Nguyen MH; Press EG; Updike CL; Clancy CJ
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6361-5. PubMed ID: 24060873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Echinocandin susceptibility testing of Candida isolates collected during a 1-year period in Sweden.
    Axner-Elings M; Botero-Kleiven S; Jensen RH; Arendrup MC
    J Clin Microbiol; 2011 Jul; 49(7):2516-21. PubMed ID: 21543574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.